Qynapse

Qynapse operates at the intersection of neuroimaging software, medical-device diagnostics, clinical-trial imaging, and machine learning. Its differentiated position comes from combining regulated clinical software with research-oriented predictive analytics rather than offering only general-purpose image interpretation. QyScore® is described as FDA-cleared and CE-marked, with capabilities covering MRI preprocessing, quality control, brain-structure and lesion labeling, visualization, and volumetric quantification. QyPredict® extends the platform into research use by integrating neuroimaging with genomics, biofluids, cognitive measures, and activities-of-daily-living data to investigate individual disease trajectories. The July 2022 Calyx partnership provides evidence of applicability to CNS clinical-trial operations, while the 2025 Alzheimer’s data announcement shows continued focus on disease progression. Within its stated categories, Qynapse appears focused on a specialized, high-regulation segment where clinical validation, workflow integration, and regulatory status may be more important than broad consumer reach. Its Paris base and reported operations in France, the United States, and Canada support an international operating scope.

Qynapse has followed a staged development path from research spin-off to regulated neuroimaging software company. Founded in 2015, it recorded an early venture round that year with AGORANOV as the identified investor. Two subsequent seed rounds raised $1.8 million each on July 1, 2018, and October 10, 2020, followed by a $3 million seed round on June 24, 2021. Total recorded funding is $6.6 million across four rounds, although the 2015 round has no disclosed amount. Product and regulatory milestones preceded the latest financing: QyScore® received FDA clearance on February 3, 2020, and the company acquired True Positive Medical Devices on October 13, 2020. The September 2021 rebrand and October 2021 appointment of Adam Schwarz, Ph.D., as Chief Scientific Officer marked an effort to scale the corporate and scientific platform. The 2022 Calyx partnership expanded clinical-trial applicability, while the 2025 QyScore® and QyPredict® data release indicates movement toward predictive disease-progression research.